Bristol-Myers Squibb Co vs Teradyne, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $63.41 (market cap $129.94B), while Teradyne, Inc. trades at $388.87 (market cap $59.34B). The key difference: Bristol-Myers Squibb Co is far larger — about 2.2× Teradyne, Inc.'s market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | TER | |
|---|---|---|
Market Cap | $129.94B | $59.34B |
Sector | Health | Technology |
52-Week High | $65.89 | $483.84 |
52-Week Low | $42.60 | $109.30 |
Enterprise Value | $163.92B | $59.09B |
Dividend Yield | 3.96% | 0.14% |
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →